Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating the addition of navtemadlin to standard cytarabine and idarubicin in patients with acute myeloid leukemia (including AM…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Idarubicin (idarubicin)
• Navtemadlin (navtemadlin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1 | Status: ACTIVE_NOT_RECRUITING